ABOUT US
Investors
Alta Partners
Alta Partners is a San Francisco based venture capital firm founded in 1996, currently managing seven venture fund programs aggregating approximately $2 billion in committed capital. Alta has invested over $800 million in more than 110 life sciences companies. The firm invests in both early and later stage companies, through separate stage-specific funds. Alta Partners is a successor to Burr, Egan, Deleage & Co., which was founded in 1979.
www.altapartners.com
Clarus Ventures
Clarus Ventures is a venture capital firm with offices in South San Francisco and Cambridge, MA. With over $500 million in committed capital Clarus began funding biopharmaceutical and specialty pharma companies in early 2006. Clarus Ventures was founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development, and operations management at the global level.
www.clarusventures.com
GBS Ventures
GBS Venture Partners (GBS) is a leading life science venture capital group resulting from a November 2002 management buyout of Rothschild Bioscience Managers Limited from NM Rothschild & Sons (Aust) Ltd. GBS invests in and adds value to unlisted high growth companies involved in innovative technologies and invests at the seed, start-up or early expansion stage of company development. GBS manages AUS $150 million in life science specialist funds, aiming to make a significant commitment to building life science based companies.
www.gbsventures.com.au
Delphi Ventures
Delphi Ventures is a San Francisco based venture capital firm that has focused on early stage investing in medical device and biotechnology companies since it's founding in 1988. With more than $850 million in committed capital, Delphi Ventures has funded over 150 companies. Total capital raised by Delphi Venture companies over the years is more than $3.5 billion. More than 90 of their portfolio companies have either completed an initial public offering or have been acquired by a leading healthcare corporation.
www.delphiventures.com
No 8 Ventures
Founded in 1999, No 8 Ventures manages the No 1 Fund and the No 2 Fund/VIF Seed Fund and has more than $60 million of funds under management, which are invested, or available for investment, in seed, start-up and early expansion NZ based technology enterprises. Following an investment the partners from No 8 Ventures engage actively with the companies, forming partnerships with the founders and executives to help them grow significant international businesses.
www.no8ventures.co.nz
Endeavour i-cap
A partnership between Endeavour Capital and i-cap partners, Endeavour Capital is a leading New Zealand early stage venture capital company, investing into New Zealand growth opportunities. Established in 1999, Endeavour Capital has a focus on developing globally competitive companies based on science and technology innovations. To date Endeavour Capital has made investments across biotechnology, software and medical sectors. i-cap Partners, formed in 1999, is New Zealand 's largest private equity firm, with NZ$400 million under management and offices in Auckland, London, San Francisco and Bahrain.
www.ecap.co.nz
Roche
Roche, based in Switzerland, is a leading healthcare company with a uniquely broad spectrum of innovative solutions. For more than 100 years, it has been active in the discovery, development, manufacture, and marketing of novel healthcare solutions. Roche's products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life. The Roche Venture Fund invests in early stage biotech and diagnostics companies to support innovative technologies and medicines. Roche Venture Fund invests globally with a portfolio of over 25 investments in ten countries. Proacta is Roche Venture Fund's first investment in New Zealand. Roche Venture Fund is based in Basel, Switzerland.
www.roche.com
Genentech
Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. Eighteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 12 biotechnology products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For press releases and additional information about the company, visit their website.
www.gene.com
Auckland UniServices Limited
Auckland UniServices Limited is the commercial research and knowledge transfer company of The University of Auckland. UniServices is wholly owned by the University, manages the University's commercial research contracts, owns and commercializes its intellectual property estate, and forms new companies based around the University's intellectual property. UniServices generates revenues in excess of NZD $62 million, directly employs 470 research staff and is now the largest organization commercializing university research in Australasia.
www.uniservices.co.nz
